Abstract 93P
Background
Immune system plays an important role in the development, treatment response, and progression of triple-negative breast cancer. Here, we aimed to assess the dynamics of cell populations and their transcriptome changes during neoadjuvant chemotherapy (NACT) in triple-negative breast cancer patients.
Methods
Mononuclear cells were purified from peripheral venous blood before NACT, after 3rd and 21st days of NACT using a ficoll density gradient. Total cell concentration and viability (Calcein/DRAQ7) were assessed by flow cytometry (Cytoflex, Beckman Coulter). Single cells were sequenced on a NextSeq 2000 (Illumina) using targeted panel Immune Response from Rhapsody Express (Becton Dickinson). Data were analyzed using Seurat and SingleR.
Results
According to single cell sequencing data we revealed 10 main populations of mononuclear leukocytes: В cells (CD79+), NK cells (KIR2DL+), classical (CD14+) and non-classical (CD16+) monocytes, Т-cytotoxic cells (CD8+), Т-helpers (CD4+), T-regs (FOXP3+), CD4 memory cells (CD4+, IL32+, KLRB+, RGS1+), CD8 naïve (CD8+, LEF1+, CCR7+, PIK3IP1+), CD4 naïve (CD4+, LEF1+, CCR7+, PIK3IP1+). 3 days after NACT overexpression of BAX, FOSb, JUN, CXCR4, CD69 genes were observed, that mediating apoptosis of CD4 memory/naïve and CD8 naïve lymphocytes, T regs and monocytes; chemotaxis and proliferation of NK and Т-cytotoxic lymphocytes. The population of blood monocytes was selectively depleted (up to 3%). 21 days after NACT overexpression of CCR2, S100A9, ITGAM, CXCL8, CCL4, CCL5 genes were observed, mediating migration of monocytes to tissue, chemotaxis of immune cells and inflammation. The population of monocytes increased by up to 20%.
Conclusions
Chemotherapy affects the quantitative and qualitative composition of mononuclear leukocytes and changes their transcriptomic profile towards proinflammatory activation. This study was funded by the Russian Science Foundation (grant #22-75-10128).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation, no.22-75-10128.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
67P - The effect of non-viral gene-immune therapy via OX40L or 4-1BBL on murine subcutaneous CT26 colon cancer model
Presenter: Olga Rakitina
Session: Poster session 09
68P - Dendritic polylysine with paclitaxel and triptolide codelivery for enhanced NSCLC ferroptosis through the accumulation of ROS
Presenter: Huae Xu
Session: Poster session 09
69P - Novel monoclonal antibodies can distinguish Cripto-1 from Cripto-3 proteins: Clinical implications and potential new biomarkers
Presenter: Josune Garcia-Sanmartin
Session: Poster session 09
70P - The human intratumor mycobiome is significantly influenced by an individual's race
Presenter: Dan Coster
Session: Poster session 09
71P - Preclinical characterization of ARX305: A next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers
Presenter: Lillian Skidmore
Session: Poster session 09
72P - Impact of extended panel of genes for germline cancer testing
Presenter: Shaheenah Dawood
Session: Poster session 09
73P - Preclinical and clinical presentation of the nerve-driven tumor spread
Presenter: Dawid Sigorski
Session: Poster session 09
74P - Characterization of ERBB2 variation and their association with immune response in solid tumours
Presenter: Dong Wang
Session: Poster session 09
75P - Double-stranded RNA transfection induced anti-tumour effect mediated by dual RIG-I and TLR-3 immune pathways
Presenter: Jiayu Tai
Session: Poster session 09
76P - Improvement of whole-cell cancer vaccine anti-tumor effect by different injection methods
Presenter: Chin yang Chang
Session: Poster session 09